Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, and German Centre of Neurodegenerative Diseases (DZNE), University Hospital and University Tübingen, Tübingen, Germany.
Institute for Neuromodulation and Neurotechnology, University Hospital and University of Tübingen, Tübingen, Germany.
J Parkinsons Dis. 2023;13(4):563-573. doi: 10.3233/JPD-225031.
BACKGROUND: Axial symptoms of Parkinson's disease (PD) can be debilitating and are often refractory to conventional therapies such as dopamine replacement therapy and deep brain stimulation (DBS) of the subthalamic nuclei (STN). OBJECTIVE: Evaluate the efficacy of bilateral DBS of the pedunculopontine nucleus area (PPNa) and investigate structural and physiological correlates of clinical response. METHODS: A randomized, double-blind, cross-over clinical trial was employed to evaluate the efficacy of bilateral PPNa-DBS on axial symptoms. Lead positions and neuronal activity were evaluated with respect to clinical response. Connectomic cortical activation profiles were generated based on the volumes of tissue activated. RESULTS: PPNa-DBS modestly improved (p = 0.057) axial symptoms in the medication-off condition, with greatest positive effects on gait symptoms (p = 0.027). Electrode placements towards the anterior commissure (ρ= 0.912; p = 0.011) or foramen caecum (ρ= 0.853; p = 0.031), near the 50% mark of the ponto-mesencephalic junction, yielded better therapeutic responses. Recording trajectories of patients with better therapeutic responses (i.e., more anterior electrode placements) had neurons with lower firing-rates (p = 0.003) and higher burst indexes (p = 0.007). Structural connectomic profiles implicated activation of fibers of the posterior parietal lobule which is involved in orienting behavior and locomotion. CONCLUSION: Bilateral PPNa-DBS influenced gait symptoms in patients with PD. Anatomical and physiological information may aid in localization of a favorable stimulation target.
背景:帕金森病(PD)的轴性症状可能使人衰弱,并且通常对常规治疗(如多巴胺替代疗法和丘脑底核(STN)的深部脑刺激(DBS))有抗性。 目的:评估苍白球内侧区(PPNa)双侧 DBS 的疗效,并研究与临床反应相关的结构和生理相关性。 方法:采用随机、双盲、交叉临床试验评估双侧 PPNa-DBS 对轴性症状的疗效。根据临床反应评估导引线位置和神经元活动。根据激活的组织体积生成皮质连接激活图。 结果:PPNa-DBS 在药物停用状态下适度改善(p=0.057)轴性症状,对步态症状的积极影响最大(p=0.027)。电极放置在前连合(ρ=0.912;p=0.011)或盲孔(ρ=0.853;p=0.031)附近,靠近脑桥中脑交界处的 50%标记处,可获得更好的治疗反应。治疗反应更好的患者(即电极位置更靠前)的记录轨迹中的神经元具有更低的放电率(p=0.003)和更高的爆发指数(p=0.007)。结构连接组学图谱提示激活了与定向行为和运动有关的顶叶后皮质纤维。 结论:双侧 PPNa-DBS 影响 PD 患者的步态症状。解剖学和生理学信息可能有助于确定有利的刺激靶点。
J Neurol Neurosurg Psychiatry. 2014-9-2
J Neuroeng Rehabil. 2025-9-9
Stereotact Funct Neurosurg. 2021
Neuroimage. 2020-10-1
Front Aging Neurosci. 2018-4-26